Compare Goodyear Tire & Rubber Co (GT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GT trades at $7.18, up 7.81% today, with a bullish technical signal and moving average alignment. The stock shows attractive valuation ratios (P/E 4.69, P/B 0.64) but faces profitability challenges, with a net income margin of -11.64% in 2025. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering. Q1 2026 earnings beat estimates, yet revenue trends are declining.

Outlook: Deep value metrics and analyst consensus target of $8.75 suggest upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Investors should weigh low valuation against operational headwinds and macroeconomic sensitivity.

Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.

Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.